Project Grant R43PS005313

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline...

This Project Grant award, totaling $354,570.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a cost-effective and user-friendly point-of-care (POC) diagnostic tool, employing a novel "CamoChip" technology, for highly sensitive and multiplex testing of biomarkers related to HIV/HBV co-infection. The key products and services to be delivered under...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $233,666 Project Grant to Esper Biosciences Inc. in Ithaca, NY on September 30, 2025 under the CDC Investigations and Technical Assistance program (CFDA 93.283). The grant funding supports the development of a rapid point-of-care nucleic acid test for Hepatitis C using nanosensors. This project aligns with the CDC program's goals of controlling communicable diseases and developing innovative health technologies. The award has...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $776,341 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois on September 16, 2025. The purpose of this grant is to develop a microfluidic cartridge, molecular biology method, biosensor, and detection instrument that can simultaneously detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) viral loads from a minimal 100 μL whole blood sample. This...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $501,200 Project Grant on Sep 30, 2025 to Aptus Biosciences LLC, a minority-owned small business located in Gainesville, Florida, under the CDC's "Prevention of Disease, Disability, and Death by Infectious Diseases" program (CFDA 93.084). The funding will support the development of a rapid, affordable, aptamer-based diagnostic test for Hepatitis C virus. Aptus Biosciences specializes in advanced diagnostic research and...

The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...

This $305,352 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) supports the development of a quantitative, home monitoring point-of-care test for determining total blood homocysteine (THCY) levels. The funding will allow Analytical Diagnostic Solutions Inc., a for-profit S corporation based in New Jersey, to create the "HCY NOW" device, which aims to significantly improve the management of homocystinurias (HCUs) - a group of...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Teardx, LLC will fund the development of a rapid, point-of-care diagnostic test to accurately detect ocular herpes simplex virus (HSV-1) infections. The project aims to create a user-friendly, minimally invasive sampling tool and assay that can be used by eye specialists and urgent care clinicians to quickly screen for active HSV-1 infections, which are a leading cause...